WallStreetZenWallStreetZen

NASDAQ: CYTK
Cytokinetics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

CYTK past revenue growth

How has CYTK's revenue growth performed historically?
Company
-92.04%
Industry
145.73%
Market
17.2%
CYTK's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CYTK's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CYTK's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CYTK earnings and revenue history

Current Revenue
$7.5M
Current Earnings
-$526.2M
Current Profit Margin
-6,988.6%

CYTK Return on Equity

Current Company
N/A
Current Industry
-63.5%
Current Market
188%

Be the first to know when CYTK announces earnings.

CYTK Return on Assets

Current Company
-65.1%
Current Industry
2.9%
CYTK is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CYTK Return on Capital Employed

Current Company
-69%
Current Industry
19.5%
CYTK's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CYTK vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CYTK$7.53M-$486.05M-$526.24M-24.89%N/A
JAZZ$3.83B$1.22B$414.83M+15.19%-2.54%
PCVX$0.00-$392.10M-$402.27MN/AN/A
EXEL$1.83B$312.21M$207.77M+16.47%-22.47%
IONS$787.65M-$230.01M-$366.29M+5.60%N/A
View Top Biotech Stocks

CYTK earnings dates

Next earnings date
May 2, 2024

Cytokinetics Earnings & Revenue FAQ

What were CYTK's earnings last quarter?

On Invalid Date, Cytokinetics (NASDAQ: CYTK) reported Q4 2023 earnings per share (EPS) of -$1.38, up 6.76% year over year. Total Cytokinetics earnings for the quarter were -$136.90 million. In the same quarter last year, Cytokinetics's earnings per share (EPS) was -$1.48.

If you're new to stock investing, here's how to buy Cytokinetics stock.

What was CYTK's earnings growth in the past year?

As of Q2 2024, Cytokinetics's earnings has grown year over year. Cytokinetics's earnings in the past year totalled -$526.24 million.

What is CYTK's earnings date?

Cytokinetics's earnings date is Invalid Date. Add CYTK to your watchlist to be reminded of CYTK's next earnings announcement.

What was CYTK's revenue last quarter?

On Invalid Date, Cytokinetics (NASDAQ: CYTK) reported Q4 2023 revenue of $1.67 million up 14.56% year over year. In the same quarter last year, Cytokinetics's revenue was $1.96 million.

What was CYTK's revenue growth in the past year?

As of Q2 2024, Cytokinetics's revenue has grown -92.04% year over year. This is 237.77 percentage points lower than the US Biotechnology industry revenue growth rate of 145.73%. Cytokinetics's revenue in the past year totalled $7.53 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.